Cargando…
表皮生长因子受体酪氨酸激酶抑制剂在晚期非小细胞肺癌一线治疗中的应用
BACKGROUND AND OBJECTIVE: Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) has been widely used as the second- and third-line therapy in patients with advanced non-small cell lung cancer (NSCLC). However, its effect in the first-line treatment is unclear. The aim of this study w...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
中国肺癌杂志编辑部
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6000684/ https://www.ncbi.nlm.nih.gov/pubmed/20672704 http://dx.doi.org/10.3779/j.issn.1009-3419.2010.01.09 |
Ejemplares similares
-
表皮生长因子酪氨酸激酶抑制剂一线治疗突变阳性晚期非小细胞肺癌的临床疗效预测因素分析
Publicado: (2019) -
非小细胞肺癌脑转移患者接受一代表皮生长因子受体酪氨酸激酶抑制剂治疗的临床研究
Publicado: (2017) -
酪氨酸激酶抑制剂耐药机制及其治疗策略
Publicado: (2011) -
表皮生长因子受体突变细胞系H1650耐药机制探讨
Publicado: (2012) -
抗表皮生长因子受体和抗血管内皮生长因子药物在非小细胞肺癌治疗中的作用
por: LANGER, Corey, et al.
Publicado: (2010)